When was Pharmaron founded?

Pharmaron was founded in 2003 and raised its 1st funding round 5 years after it was founded.

Where is Pharmaron located?

Pharmaron is headquartered in Beijing, China. It is registered at Baltimore, Maryland.

Who is the current CEO of Pharmaron?

Boliang Lou of Pharmaron. They have also founded 1 company.

How many employees does Pharmaron have?

As of Dec 31, 2021, Pharmaron has 476 employees, reflecting a 124% year-over-year growth in headcount.

Is Pharmaron a funded company?

Pharmaron is a funded company, having raised a total of $320M across 5 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 20, 2008.

When was the latest funding round of Pharmaron?

Pharmaron's latest funding was a $***** PE round on Dec 14, 2015, with participation from 2 investors.

Where does Pharmaron rank among its competitors?

Pharmaron ranks 1st amongst 756 active competitors, of which 42 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Shenshi Technology, which secured $114M in Dec, 2025.

Who are the top competitors of Pharmaron?

Pharmaron's top competitors include Pfizer, Boehringer Ingelheim and Lonza. Among them, Shenshi Technology secured the most recent funding round in December, 2025.

Pharmaron - 2026 Company Profile, Team, Funding & Competitors

Pharmaron is a public company based in Beijing (China), founded in 2003 by Bei Zheng, Larry Lou and Boliang Lou. It operates as a Suite of drug discovery and development services for small molecules. Pharmaron has raised $320M in funding from Legend Capital and Gl-investment. The company has 756 active competitors, including 42 funded and 71 that have exited. Its top competitors include companies like Pfizer, Boehringer Ingelheim and Lonza.

Company Details

Pharmaron offers a suite of drug discovery and development services for small molecules, nucleosides, nucleotides, peptides, lipids and carbohydrates. They offer their R&D services across a number of disciplines including chemistry, biology, DMPK, pharmacology, toxicology and chemical and formulation development. The company claims that their chemistry division is one of the largest chemistry service providers in the world with experience and expertise in organic synthesis, library/high-throughput synthesis, chiral chemistry, medicinal, computational and cheminformatics, bioorganic chemistry, process and scale-up, analytical and purification. Their biologics division offers services such as antibody/protein engineering, antibody humanization, cell line development, recombinant antibody production, protein expression, purification, and characterization.The company has acquired Xceleron and SNBL CPC to augment its offerings.

Website: www.pharmaron.com
Social
Registered Address: Baltimore, Maryland

Key Metrics

Founded Year

2003

Location

Beijing, China

Stage

Public

Total Funding

$320M in 5 rounds

Latest Funding Round

PE, Dec 14, 2015, $*****

Investors

Legend Capital & 12 more

Ranked

1^st among 756 active competitors

Employee Count

476 as on Dec 31, 2021

Investment & Acquisitions

Aesica & 14 more

Similar Companies

Pfizer & 815 more

Exit Details

Public

View Pharmaron's full profile

Pharmaron is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
PHARMARON INC CIN: 208419781 , United States, Active	Dec 31, 1999	-	476 (As on Dec 31, 2021)	-
Pharmaron Manufacturing Services (uk) Ltd CIN: 5188033 , United Kingdom, Active	Jul 22, 2004	$6.3M (As on Dec 31, 2022)	138 (As on Dec 31, 2024)

Pharmaron got listed on Feb 01, 2019.

Click here to take a look at Pharmaron's IPO in detail

Pharmaron has raised a total funding of $320M over 5 rounds. Its first funding round was on Sep 20, 2008. Its latest funding round was a PE round on Dec 14, 2015 for $*****. 2 investors participated in its latest round. Pharmaron has 13 institutional investors.

Here is the list of recent funding rounds of Pharmaron:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 14, 2015	6367609	PE	5769006	6010269	8803820	9568068
Mar 01, 2011	9724923	Series C	1871357	9888140	7229580	Legend Capital & 2 more
Sep 25, 2009	9895967	Grant (prize money)	1062331	5521308	8516643	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Pharmaron's funding rounds and investors

The founders of Pharmaron are Bei Zheng, Larry Lou and Boliang Lou. Boliang Lou is the CEO of Pharmaron.

Here are the details of Pharmaron's key team members:

Bei Zheng: Co-Founder of Pharmaron.
Contact Info: 1 email address
Larry Lou: Co-Founder of Pharmaron.
Contact Info: 1 email address
Boliang Lou: Co-Founder & CEO of Pharmaron.
Contact Info: 1 email address

View details of Pharmaron's Founder profiles and Board Members

Pharmaron's employee count trend

Pharmaron has 476 employees as of Dec 21. The total employee count is 123.0% more than what it was in Dec 20. Here is Pharmaron's employee count trend over the years:

Uncover Pharmaron's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Pharmaron include Pfizer, Boehringer Ingelheim and Lonza. Here is the list of Top 10 competitors of Pharmaron, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Pharmaron 2003, Beijing (China), Public	Suite of drug discovery and development services for small molecules	$320M	Aisling Capital, CITIC Capital & 11 others	76/100
2nd	Pfizer 1849, New York City (United States), Public	Provider of pharmaceutical products for multiple disease treatments	-	Black Capital Investments, Alcor Fund & 16 others	73/100
3rd	Boehringer Ingelheim 1885, Ingelheim am Rhein (Germany), Funding Raised	Provider of generic drugs and clinical research services	-	Amgen Business Development, Sanderling Ventures ... & 1 others	64/100
4th	Lonza 1897, Basel (Switzerland), Acquired	Provider of CDMO services to pharma, biotech, and specialty ingredient markets	-	Defense.gov, EDBI & 4 others	59/100
5th	Tyra 2018, Carlsbad (United States), Public	Developer of cancer resistance therapies	$156M	Boxer Capital, RA Capital Management & 6 others	59/100
6th	LabConnect 2002, Johnson City (United States), Series A	Provider of laboratory testing, clinical ttrial research, and biopharma functional services	$29.2M	Broadoak Capital Partners, ABS Capital & 5 others	58/100
7th	Clearsynth 2009, Mumbai (India), Series A	CDMO focused on manufacturing of pharmaceutical small molecules and analytical research services	$4.81M	SIDBI Venture Capital, Tulip Diagnostics & 7 others	57/100
8th	Shenshi Technology 2019, Beijing (China), Series C	Developer of AI-driven platform and tools for scientific research and development	$255M	Source Code Capital, Baidu Venture Capital ... & 22 others	55/100
9th	Matchpoint Therapeutics 2021, Cambridge (United States), Series A	Provider of small molecular medicine development and analytics services	$100M	Access Industries, Sanofi Ventures & 4 others	55/100
10th	Evergreen Theragnostics 2019, Jersey City (United States), Acquired	Provider of radiopharmaceuticals manufacturing and regulatory services	$75.9M	Petrichor, Novacapital & 4 others	52/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Pharmaron's competitors? Click here to see the top ones

Pharmaron has made 4 investments in companies including SocialMED and Eclincloud. Pharmaron has also acquired 11 companies including Aesica and Allergan.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Jan 10, 2023	Acquisition	Aesica	2004	Newcastle Upon Tyne (United Kingdom)
Oct 08, 2022	Investments	SocialMED	2017	China
Dec 01, 2021	Investments	Eclincloud	2020	Shenzhen (China)